title: Safety of the galactose-based ultrasound contrast agent levovist.
authors.affiliation: Clinical Development Diagnostics and Corporate Drug Safety, Schering AG, Berlin, Germany.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Schlief
authors.forename: Abudulai
authors.initials: A
authors.lastname: Alhassan
authors.forename: Jay
authors.initials: J
authors.lastname: Wiggins
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schumann
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Niendorf
mesh_terms: D000787:Angina Pectoris / Q000139:chemically induced; D001986:Bronchial Spasm / Q000139:chemically induced*; D003287:Contrast Media / Q000009:adverse effects*; D006801:Humans; D011134:Polysaccharides / Q000009:adverse effects*; D014463:Ultrasonography / Q000379:methods; D014581:Urticaria / Q000139:chemically induced
chemical_list: D003287:Contrast Media; D011134:Polysaccharides; C059891:SHU 508